content_image/292511.jpg content_image/292517.jpg content_image/292518.jpg content_image/292512.jpg content_image/292519.jpg content_image/292520.jpg
## Mainstay Products in Oncology 

<img src='content_image/292511.jpg'>

Fiscal 2013 sales: ¥54.6 billion 

This product is used in the treatment of prostate cancer. It was launched in the U.S. in 2012 for indications of metastatic castration-resistant prostate cancer in patients who have previously received docetaxel. It is currently sold in over 25 countries and regions, including Europe, North America and Japan. 

## Latest Innovative Products 

<img src='content_image/292517.jpg'>

## 1 Suglat for the treatment of type 2 diabetes 

Japan’s first SGLT2 inhibitor to receive approval for the treatment of type 2 diabetes. It was launched in April 2014 and we co-promote it with Kotobuki Pharmaceu- tical Co., Ltd. and MSD K.K. 

## 3 Acofide for the treatment of functional dyspepsia 

Acofide was launched in Japan in June 2013 as the first treatment for the indication of functional dyspepsia. Astellas is co-promoting Acofide with Zeria Pharmaceutical Co., Ltd. 

<img src='content_image/292518.jpg'>

<img src='content_image/292512.jpg'>

Fiscal 2013 sales: ¥44.7 billion 

This product is a low-molecule drug developed to target the epidermal growth factor receptor (EGFR) that plays a key role in cancer formation and growth. In the U.S., Astellas is co-promoting Tarceva with Genentech, Inc. In regions outside the U.S., Astellas has a license agree- ment with F. Hoffmann-La Roche Ltd. 

<img src='content_image/292519.jpg'>

## 2 cimzia for the treatment of adult patients with rheumatoid arthritis 

Cimzia is the world’s first PEGylated anti-TNF (tumor necrosis factor)-alpha antibody. It was launched in Japan in March 2013 as a treatment for rheumatoid arthritis. Astellas is co-promoting Cimzia with UCB Japan Co., Ltd. 

## 4 DiFicliR for the treatment of Clostridium difficile  infections 

DIFICLIR is an oral macrocyclic antibiotic with a selective antibiotic spectrum. It was launched in Europe in 2012 as a treatment for Clostridium difficile  infections in adults. 

<img src='content_image/292520.jpg'>

